Semaglutide and PCOS: what the evidence supports, and what it does not

Semaglutide is not approved for polycystic ovary syndrome. It is approved for chronic weight management, and PCOS is not a weight management indication. What a prescriber can assess is whether a weight management medication is appropriate for you as a person, based on your history and your current medications, not whether it treats your PCOS.

That distinction is the whole page. Everything below explains why it matters and what the published evidence does and does not establish.

The evidence

Two honest caveats sit under all of this. The PCOS-specific trials that exist are small and short, so they can show a direction and not much more. And weight reduction in PCOS is genuinely useful in the guidelines, but nothing in the evidence entitles anyone to tell you what will happen to your cycles, your symptoms or your fertility.

Before you start

Pregnancy and contraception. GLP-1 medication is not appropriate during pregnancy or when you are planning one. Weight reduction can make ovulation more likely in some people with PCOS, which means pregnancy can become more likely too. If that is not what you want right now, raise contraception before you start rather than after.

Everything else you take. Oral contraceptives, metformin, spironolactone and anything else in your PCOS regimen should be listed in your intake. GLP-1 medication slows gastric emptying, which is a reason your prescriber needs the full list rather than a summary.

Who is managing what. If a gynecologist or endocrinologist manages your PCOS, they stay in charge of it. A weight management prescription sits alongside that care, and it works better when both clinicians know about each other.

The offer

Society is 100% online. A licensed US practitioner reviews your intake, medications are dispensed through US licensed pharmacies, and delivery is free, discreet and takes 1 to 2 days. No insurance is required. Prices are starting prices, not flat prices, and the plan your provider determines is right for you sets what you pay. You can pause, switch or cancel anytime, which stops future billing cycles, and the first two months of any treatment plan are non-refundable.

Society offers injectable GLP-1 medication only, plus oral metformin. There is no oral GLP-1 here, and metformin is not a GLP-1.

Questions

The free 2-minute evaluation puts your history in front of a licensed US practitioner, who decides whether weight management treatment is appropriate for you and what it should look like. Most members hear back within a day or two. No insurance required, delivered in 1 to 2 days, free and discreet.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.